The global DNA diagnostics market size was estimated at USD 27.10 billion in 2024 and is projected to be worth around USD 57.96 billion by 2034, growing at a CAGR of 7.9% from 2025 to 2034.
The DNA diagnostics market deals with the utilization of DNA diagnostics to detect genetic markers and variations that may be associated with inherited disorders, medical conditions, and traits. The rise in investment in R&D for inherited disorders and advancements in genomics and bioinformatics is driving market growth.
In November 2024, ProPhase Labs, Inc. a next-generation biotech, genomics, and diagnostics company, announced the launch of DNA Complete, Inc., a wholly owned subsidiary, providing a groundbreaking direct-to-consumer DNA test.
The substantial concerns about privacy and ethics that arise from integrating DNA tests into treatment are posing to hamper market growth. To resolve these privacy risks data anonymization techniques should be used. Despite these restraints, the increasing utilization of precision medicine diagnostic techniques can boost market growth shortly.
In November 2023, Illumina launched an innovative liquid biopsy assay to enable comprehensive genomic profiling of solid tumours.